Catabasis Pharmaceuticals, Inc. (CATB) Shares Up -2%
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s share price shot up 2% during trading on Thursday . The company traded as high as $1.52 and last traded at $1.47. 198,626 shares traded hands during trading, a decline of 6% from the average session volume of 210,388 shares. The stock had previously closed at $1.50.
A number of research firms recently commented on CATB. Wedbush reiterated an “ourperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $9.00 price target (down previously from $11.00) on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Zacks Investment Research cut Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 19th. Finally, HC Wainwright lifted their price target on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $4.50.
The stock has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.35. The stock’s market capitalization is $32.60 million.
Catabasis Pharmaceuticals (NASDAQ:CATB) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.08. On average, equities analysts expect that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. grew its position in shares of Catabasis Pharmaceuticals by 33.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 30,000 shares during the period. Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals during the 1st quarter valued at approximately $106,000. Finally, Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals during the 2nd quarter valued at approximately $271,000. 32.90% of the stock is owned by hedge funds and other institutional investors.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.